NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD
Post# of 90
(Total Views: 148)
Posted On: 03/20/2024 5:20:51 PM
NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions,” a recent article reads. “PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African Trypanosomiasis (‘HAT’), to support new studies for treating ASD and a related condition known as Fragile X-Associated Tremor/Ataxia Syndrome (‘FXTAS’)… If these trials prove that suramin is effective, PaxMedica could not only get the drug approved for use, but also receive a special coupon from the FDA called a Priority Review Voucher (‘PRV’). This voucher, which can accelerate the review of a new drug, is quite valuable and could be sold to another pharmaceutical company for a significant amount of money. The company intends to channel these funds into conducting extensive trials for ASD and FXTAS treatment through its lead program, PAX-101 (IV Suramin)… In 2024, PaxMedica is positioned to continue its momentum, sustained by achievements in 2023. The company is working to expand its product pipeline, centered on its proprietary source of suramin.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions,” a recent article reads. “PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African Trypanosomiasis (‘HAT’), to support new studies for treating ASD and a related condition known as Fragile X-Associated Tremor/Ataxia Syndrome (‘FXTAS’)… If these trials prove that suramin is effective, PaxMedica could not only get the drug approved for use, but also receive a special coupon from the FDA called a Priority Review Voucher (‘PRV’). This voucher, which can accelerate the review of a new drug, is quite valuable and could be sold to another pharmaceutical company for a significant amount of money. The company intends to channel these funds into conducting extensive trials for ASD and FXTAS treatment through its lead program, PAX-101 (IV Suramin)… In 2024, PaxMedica is positioned to continue its momentum, sustained by achievements in 2023. The company is working to expand its product pipeline, centered on its proprietary source of suramin.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)